Australia, New Zealand Roundup: Pharmaxis, CSL, PHARMAC
This article was originally published in PharmAsia News
Executive Summary
Pharmaxis Completes Long-Term Safety Study Of Bronchitol
You may also be interested in...
Australian Pharmaxis Reports Positive Results From Phase III Bronchitol Cystic Fibrosis Study
PERTH, Australia - Sydney-based Pharmaxis announced Dec. 2 positive headline results from its second Phase III trial of Bronchitol (mannitol) in people with cystic fibrosis
Australian Pharmaxis Reports Positive Results From Phase III Bronchitol Cystic Fibrosis Study
PERTH, Australia - Sydney-based Pharmaxis announced Dec. 2 positive headline results from its second Phase III trial of Bronchitol (mannitol) in people with cystic fibrosis
Australia's Pharmaxis Breathing Easier Following U.S. FDA Advisory Committee Recommendation For Bronchial Test Aridol
PERTH, Australia - Sydney-based Pharmaxis is breathing easier following a positive recommendation from U.S. FDA's Pulmonary-Allergy Drugs Advisory Committee Nov. 20 for approval of its bronchial test Aridol